AnaptysBio Shares Rise on FDA Approval of Jemperli as First Immunotherapy for MSI-H/dMMR Rectal Cancer
FDA grants accelerated approval to Jemperli for stage II/III MSI-H/dMMR rectal cancer, sending AnaptysBio stock higher on royalty potential.
FDA grants accelerated approval to Jemperli for stage II/III MSI-H/dMMR rectal cancer, sending AnaptysBio stock higher on royalty potential.
The deal adds siRNA technology and closes in Q1 2027.
Following a second Phase 3 miss for Duravyu in wet AMD, EyePoint will cut more than half its workforce, end the wet AMD studies early, and focus resources on its DME program.
Disc Medicine’s bitopertin succeeded on all primary and secondary endpoints in the APOLLO Phase 3 trial, sending the stock sharply higher.
The drug remains approved for other kidney diseases.
Positive REMAIN-1 data failed to support Fractyl’s valuation. Shares halved on modest effect size, cash runway, and remaining risks.